recent
year
unexpect
outbreak
infecti
diseas
caus
emerg
reemerg
virus
becom
frequent
possibl
due
environment
chang
outbreak
result
loss
life
econom
hardship
vaccin
therapeut
develop
prevent
treatment
infecti
diseas
review
summar
discuss
latest
progress
develop
smallmolecul
viral
inhibitor
highli
pathogen
coronavirus
includ
sever
acut
respiratori
syndrom
coronaviru
middl
east
respiratori
syndrom
coronaviru
ebola
viru
zika
viru
virus
interfer
specif
step
viral
life
cycl
block
bind
viru
host
cell
disrupt
viral
endocytosi
disturb
membran
fusion
interrupt
viral
rna
replic
translat
therebi
demonstr
potent
therapeut
effect
variou
emerg
reemerg
virus
also
discuss
gener
strategi
develop
smallmolecul
viral
inhibitor
recent
year
increas
outbreak
emerg
reemerg
viru
diseas
threaten
human
public
health
econom
stabil
worldwid
epidem
possibl
caus
anthropogen
social
behavior
chang
late
earli
mani
patient
acut
respiratori
diseas
symptom
guangdong
provinc
china
infect
new
coronaviru
call
sever
acut
respiratori
syndrom
coronaviru
sarscov
viru
spread
rapidli
countri
caus
case
sar
result
nearli
death
case
fatal
rate
anoth
new
coronaviru
name
middl
east
respiratori
syndrom
coronaviru
merscov
also
spread
throughout
countri
result
confirm
case
death
case
fatal
rate
latest
outbreak
ebola
viru
ebov
diseas
evd
occur
west
africa
ebovinfect
case
evdrel
death
case
fatal
rate
approxim
final
start
zika
viru
zikv
initi
caus
local
outbreak
brazil
quickli
spread
countri
area
africa
unit
state
asia
pacif
rim
zikv
infect
harm
human
nervou
system
male
reproduct
system
may
caus
develop
microcephali
fetus
zikvinfect
pregnant
women
increas
global
mani
emerg
reemerg
viral
infecti
diseas
report
worldwid
therebi
highlight
import
develop
effect
vaccin
therapeut
prevent
treatment
infecti
diseas
antivir
drug
smallmolecul
viral
inhibitor
target
variou
stage
viral
life
cycl
exampl
antihiv
drug
inhibit
viral
infect
target
viral
protein
function
differ
stage
hiv
replic
surfac
glycoprotein
gp
revers
transcriptas
integras
proteas
smallmolecul
viral
inhibitor
produc
larg
scale
appli
consider
popul
lower
cost
antibodybas
drug
high
thermost
make
easi
store
transport
use
tropic
subtrop
area
inhibitor
also
taken
oral
accept
administr
rout
smallmolecul
viral
inhibitor
review
summar
advanc
research
develop
smallmolecul
viral
inhibitor
emerg
reemerg
virus
includ
sarscov
merscov
ebov
zikv
research
develop
smallmolecul
viral
inhibitor
emerg
reemerg
virus
sarscov
merscov
belong
coronavirus
envelop
virus
consist
singlestrand
posit
rna
encod
nonstructur
structur
protein
includ
spike
envelop
e
membran
nucleocapsid
protein
sarscov
attach
target
cell
bind
receptorbind
domain
rbd
subunit
protein
cellular
receptor
angiotensinconvert
enzym
target
cell
coronaviru
enter
target
cell
mainli
via
endosom
pathway
endocytosi
protein
chang
conform
acid
environ
result
format
sixhelix
bundl
fusion
core
afterward
viral
genom
rna
releas
fusion
pore
cytoplasm
replic
final
progeni
virion
releas
exocytosi
merscov
bind
target
cell
via
interact
rbd
cellular
receptor
name
dipeptidyl
peptidas
subsequ
enter
cell
mainli
plasma
membran
fusion
life
cycl
sarscov
merscov
shown
fig
number
smallmolecul
viral
inhibitor
target
differ
stage
coronaviru
life
cycl
includ
sarscov
merscov
report
first
group
inhibitor
consist
abil
block
attach
viru
host
cell
rbd
subunit
protein
play
critic
role
viral
entri
stage
base
specif
bind
host
receptor
peptid
overlap
either
sarscov
rbd
region
term
peptid
bind
motif
term
peptid
inhibit
entri
sarscov
vero
cell
pseudotyp
viru
hela
cell
second
group
inhibitor
consist
disrupt
fig
schemat
diagram
life
cycl
coronavirus
sarscov
merscov
smallmolecul
viral
inhibitor
classifi
specif
group
accord
differ
mechan
action
angiotensinconvert
enzym
human
dipeptidyl
peptidas
viral
endocytosi
chlorpromazin
inhibitor
endocytosi
identifi
suppressor
merscov
infect
micromolar
concentr
screen
approv
compound
third
group
inhibitor
consist
capac
interrupt
membran
fusion
block
sarscov
infect
bind
domain
protein
suggest
possibl
hinder
viruscel
fusion
peptid
overlap
heptad
repeat
domain
domain
protein
inhibit
coronaviru
infect
micromolar
level
interrupt
format
instanc
block
sarscov
entri
vero
cell
inhibit
merscov
infect
effici
intranas
applic
analog
improv
solubl
stabil
could
significantli
reduc
titer
merscov
lung
mice
peptid
deriv
mous
could
enter
cell
along
virion
prevent
endosom
acidif
therebi
obstruct
membran
fusion
sarscov
merscov
penetr
deep
pocket
interfer
interact
coronaviru
hydrophob
forc
consequ
inhibit
entri
pseudotyp
sarscov
merscov
given
cathepsin
l
catl
facilit
conform
chang
protein
endosom
low
ph
catl
inhibitor
oxocarbaz
effect
inhibit
coronaviru
infect
fourth
group
inhibitor
includ
interrupt
viral
rna
replic
translat
small
interf
rna
sirna
aim
silenc
leader
sequenc
sarscov
reduc
mrna
abund
consequ
suppress
viral
replic
vero
cell
furthermor
sirna
duplex
direct
proteincod
region
sarscov
could
reduc
viral
copi
respiratori
tract
reliev
symptom
sarscovinfect
rhesu
macaqu
ribavirin
nucleosid
analog
suppress
merscov
infect
vitro
helicas
inhibitor
block
replic
sarscov
merscov
coronaviru
proteas
inhibitor
compound
also
suppress
viral
replic
fifth
group
inhibitor
includ
undefin
mechan
action
accord
highthroughput
screen
fda
drug
librari
clinic
use
drug
includ
estrogen
receptor
inhibitor
tamoxifen
citrat
toremifen
citrat
dna
metabol
inhibitor
gemcitabin
hydrochlorid
display
signific
antivir
effect
undefin
mechan
studi
mechan
action
sarscov
merscov
infect
potenti
repurpos
use
describ
approach
warrant
inhibitor
sarscov
merscov
shown
tabl
fig
ebov
negativesens
singlestrand
envelop
rna
viru
approxim
kb
genom
encod
seven
structur
protein
includ
two
gp
four
virion
protein
vp
one
nucleoprotein
np
one
nonstructur
protein
name
rnadepend
rna
polymeras
rdrp
l
protein
similar
filovirus
ebov
viral
pathogen
caus
hemorrhag
fever
evd
high
mortal
recent
epidem
evd
west
africa
claim
mani
live
therebi
highlight
import
develop
antiebov
therapeut
entri
ebov
host
cell
first
critic
step
life
cycl
initi
interact
viral
surfac
protein
receptor
host
cell
cell
immunoglobulin
mucin
domain
viru
attach
cell
surfac
intern
endosom
enclos
acid
environ
within
acid
compart
bind
niemannpick
cleav
proteas
catl
catb
trigger
membran
fusion
afterward
viral
rna
genom
releas
cytoplasm
host
cell
replic
host
metabol
pathway
util
viral
replic
transcript
viral
genom
np
l
protein
particip
final
process
assembl
bud
allow
newli
infecti
virion
invad
neighbor
cell
life
cycl
step
attract
target
develop
therapeut
agent
ebov
infect
fig
number
smallmolecul
viral
inhibitorbas
antiebov
drug
candid
target
differ
stage
viral
life
cycl
preclin
clinic
develop
first
inhibitor
disrupt
viral
endocytosi
macropinocytosi
primari
endocyt
pathway
intern
ebov
demand
equilibria
divers
ion
insid
outsid
cell
amilorid
deriv
nethylnisopropyl
amilorid
disturb
balanc
inhibit
entri
ebov
host
cell
second
inhibitor
also
disturb
membran
fusion
broadspectrum
antivir
compound
envelop
virus
restrict
entri
ebov
intercal
viral
membran
disrupt
critic
step
membran
fusion
moreov
modifi
antiebov
peptid
eg
tatebo
consist
residu
ebov
argininerich
sequenc
tat
space
glysergli
linker
accumul
endosom
block
format
oxocarbaz
inhibitor
catl
respons
process
gp
block
pseudotyp
ebov
infect
cell
viral
inhibitor
discov
highthroughput
screen
compound
bind
hydrophob
pocket
gp
ebov
seventeen
cation
amphiphil
drug
identifi
fdaapprov
drug
librari
show
consider
potent
antiebov
activ
target
exampl
bepridil
sertralin
could
block
membran
fusion
step
protect
mice
ebov
infect
third
inhibitor
interrupt
viral
rna
replic
translat
favipiravir
broadspectrum
inhibitor
rna
polymeras
suppress
ebov
replic
vero
cell
protect
type
interferon
receptordefici
mice
ebov
infect
adenosin
analog
could
suppress
infect
confer
protect
rodent
model
ebov
filovirus
atovaquon
azacitidin
disrupt
biosynthesi
pyrimidin
mycophenol
mofetil
delet
guanosin
triphosph
pool
could
inhibit
ebov
infect
addit
sirna
act
kind
inhibitor
hinder
mrna
translat
mixtur
phosphorodiamid
morpholino
oligom
pmo
tkmebola
interfer
mrna
suppress
infect
fourth
inhibitor
exhibit
undefin
antivir
mechan
strophanthin
typic
use
heart
diseas
display
antiebov
effect
drug
screen
antiebov
drug
act
differ
stage
viral
life
cycl
shown
tabl
fig
zikv
mosquitoborn
flaviviru
singlestrand
posit
rna
viru
approxim
kb
genom
contain
open
read
frame
encod
three
structur
protein
seven
nonstructur
protein
isol
rhesu
macaqu
zikv
ignor
long
time
intermitt
outbreak
occur
pacif
island
unit
state
recent
global
pandem
began
brazil
attract
extens
attent
due
possibl
associ
neurolog
complic
despit
progress
target
underli
molecular
mechan
pathogen
antizikv
drug
approv
clinic
use
date
first
step
zikv
life
cycl
attach
host
cell
mediat
interact
viru
specif
receptor
host
cell
axl
ligand
intern
clathrindepend
endocytosi
viru
undergo
uncoat
induc
special
acid
environ
endosom
fusion
viral
envelop
endosom
membran
facilit
transform
viral
envelop
protein
fusionact
state
subsequ
viral
rna
genom
releas
cytoplasm
replic
replic
complex
form
viral
nonstructur
protein
probabl
host
protein
complex
also
assist
synthesi
viral
genom
rna
capsid
protein
viral
structur
protein
combin
rna
genom
form
nucleocapsid
core
viral
assembl
occur
endoplasm
reticulum
bud
obtain
lipid
envelop
progeni
viru
final
releas
exocytot
pathway
life
cycl
zikv
shown
fig
follow
outbreak
zikv
epidem
wide
varieti
smallmolecul
viral
inhibitor
report
first
categori
inhibitor
block
bind
viru
host
cell
found
peptidebas
antizikv
inhibitor
deriv
stem
region
e
protein
highli
effect
inhibit
zikv
infect
type
type
iii
interferon
receptordefici
mice
inhibitor
also
prevent
vertic
transmiss
zikv
pregnant
mice
fetus
interact
viral
surfac
envelop
e
protein
form
membran
pore
disrupt
integr
viral
membran
smallmolecul
inhibitor
preferenti
bind
affin
zikv
e
protein
reduc
viru
titer
noncytotox
concentr
use
vitro
assay
curcumin
inhibit
infect
zikv
envelop
virus
block
interact
viru
host
cell
second
categori
inhibitor
disrupt
viral
endocytosi
process
nanchangmycin
natur
bacteri
product
inhibit
zikv
infect
vitro
block
clathrinmedi
endocytosi
third
categori
inhibitor
disturb
membran
fusion
chloroquin
niclosamid
anthelmint
medic
effect
cestod
inhibit
acidif
endosom
low
phdepend
conform
chang
e
protein
necessari
membran
fusion
chloroquin
niclosamid
block
zikv
infect
vitro
experi
moreov
inhibit
zikv
infect
vitro
vivo
assay
especi
protect
rhesu
monkey
infect
reduc
viremia
durat
shorten
viral
shed
fourth
categori
inhibitor
interrupt
viral
rna
replic
translat
form
viral
proteas
complex
essenti
zikv
replic
ten
inhibitor
hcv
inhibit
zikv
replic
base
structur
similar
zikv
hcv
furthermor
show
ntpdepend
rna
helicas
domain
c
terminu
unwind
rna
contain
domain
methyltransferas
rdrp
assist
replic
process
therebi
provid
attract
target
design
zikv
therapi
sofosbuvir
inhibitor
zikv
rdrp
suppress
viral
replic
cell
recent
temoporfin
demonstr
inhibit
zikv
infect
vitro
vivo
disturb
polyprotein
process
block
interact
addit
polymeras
inhibitor
inhibit
vitro
zikv
replic
effici
reliev
viremia
infect
mice
anoth
class
antivir
agent
consist
nucleosid
analog
termin
viral
rna
synthesi
nucleosid
deriv
inhibit
zikv
replic
cellular
assay
dosedepend
manner
adenosin
analog
also
protect
mice
zikv
infect
differenti
viral
translat
rna
synthesi
zikv
replicon
system
establish
screen
character
viral
replic
inhibitor
fifth
categori
inhibitor
consist
without
defin
mechan
action
control
zikv
epidem
inhibitor
undefin
mechan
vitro
vero
cell
cell
mmoll
mmoll
research
carri
highthroughput
screen
mani
compound
zikv
therapi
multidimens
includ
inhibitor
zikv
infect
placent
trophoblast
cell
neuroprotect
agent
emricasan
inhibitor
essenti
pathogen
zikv
reliev
neural
damag
caus
zikv
new
mous
model
recapitul
adulthood
sequela
congenit
zikv
infect
enabl
screen
evalu
smallmolecul
drug
repair
impair
nervou
system
fetus
directli
suppress
viral
replic
improv
prognosi
potenti
therapi
accord
life
cycl
shown
tabl
fig
review
relev
inhibitor
repres
virus
context
viral
life
cycl
basi
summari
extrapol
gener
strategi
may
guid
research
develop
smallmolecul
viral
inhibitor
viral
entri
host
cell
first
stage
viral
infect
henc
stage
attract
target
design
develop
inhibitor
variou
virus
envelop
virus
class
fusion
protein
hiv
sarscov
merscov
ebov
format
requir
facilit
fusion
viru
cell
membran
small
molecul
block
format
gener
effect
inhibit
infect
virus
sinc
first
discoveri
potent
hiv
fusion
inhibitori
peptid
clinic
applic
treatment
hiv
infect
mani
viral
fusion
inhibitori
peptid
block
format
peptid
merscov
tatebo
peptid
ebov
report
recent
develop
new
tripartit
model
design
viral
fusion
inhibitori
peptid
improv
efficaci
disturb
format
model
adapt
design
viral
inhibitor
envelop
virus
includ
may
emerg
futur
anoth
gener
strategi
suppress
viral
endocytosi
pathway
util
mani
envelop
virus
exampl
review
small
molecul
interfer
clathrinmedi
endocytosi
andor
caveolinmedi
endocytosi
eg
chlorpromazin
also
review
compound
prevent
acidif
endosom
consequ
inhibit
activ
host
proteas
endosom
critic
proteolysi
conform
chang
viral
envelop
protein
fusion
viru
endosom
membran
exampl
chloroquin
catlcatb
inhibitor
fall
categori
inhibitor
gener
suppress
infect
virus
intern
endocytosi
inhibitor
common
cellular
pathway
util
differ
virus
suppress
viru
infect
broad
spectrum
howev
target
host
protein
instead
specif
viral
protein
may
rais
concern
side
effect
nonspecif
therefor
extens
vitro
experi
vivo
anim
studi
conduct
evalu
potenti
toxic
drug
candid
target
host
protein
addit
small
molecul
nucleosid
analog
eg
favipiravir
nucleosid
sirna
eg
tkmebola
pmo
eg
inhibit
activ
viral
rdrp
target
viral
rna
interfer
viral
rna
replic
transcript
translat
consequ
rna
viru
infect
suppress
final
time
effect
therapi
avail
emerg
reemerg
virus
repurpos
clinic
smallmolecul
drug
take
recent
zikv
epidem
exampl
emricasan
pancaspas
inhibitor
niclosamid
anthelmint
drug
protect
zikv
infect
gener
strategi
fig
adapt
develop
smallmolecul
viral
virus
util
host
cellular
compon
satisfi
variou
physiolog
process
includ
viral
entri
genom
replic
assembl
bud
virion
therebi
result
patholog
damag
host
therefor
key
stage
life
cycl
could
potenti
target
develop
smallmolecul
viral
inhibitor
upon
emerg
reemerg
viral
outbreak
research
use
highthroughput
screen
approach
determin
rapidli
effect
smallmolecul
viral
inhibitor
pharmacolog
compound
clinic
treatment
research
develop
stage
small
molecul
rel
inexpens
smallmolecul
viral
inhibitor
also
conveni
oral
administr
gener
therapeut
small
molecul
superior
antivir
therapi
antibodi
henc
use
widespread
develop
develop
countri
antivir
activ
smallmolecul
viral
inhibitor
typic
potent
antibodi
small
molecul
exhibit
shorter
halflif
vivo
antibodi
rel
high
toxic
also
restrict
use
especi
pregnant
women
neonat
infect
zikv
overcom
problem
repurpos
approv
clinic
safe
drug
pregnant
women
advis
altern
solut
observ
consist
lag
time
emerg
reemerg
outbreak
develop
effect
antivir
drug
addit
mani
larg
pharmaceut
compani
reluct
develop
antivir
drug
virus
potenti
caus
shortterm
epidem
unpredict
market
valu
challeng
may
address
develop
broadspectrum
crossreact
drug
may
repres
import
futur
trend
xiaohuan
wang
peng
zou
fan
wu
lu
lu
shibo
jiang
declar
conflict
interest
manuscript
review
articl
involv
research
protocol
requir
approv
relev
institut
review
board
ethic
committe
